| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04377620 Details | 2022-01-19 Interventional | 3 | 211 | Janus Kinase In… COVID-19 | Study terminated by sponsor - | |||
| NCT03255083 Details | 2022-01-19 Interventional | 1 | 13 | Osimertinib Carcinoma, Non-… Lung Neoplasms Non-small Cell … | This study was terminated based on a business decision by the Sponsor. This study was terminated based on a business decision by the Sponsor. | |||
| NCT04005209 Details | 2022-01-14 Interventional | 4 | 0 | Ketamine Acute Pain Anemia, Sickle … Anemia; Sickle-… | Decided not to open study - | |||
| NCT02817347 Details | 2022-01-13 Interventional | 1/2 | 135 | BB 1101 Dexamethasone Dexamethasone a… Piperacillin Tazobactam Otitis Otitis Media Otorrhea | Sponsor's decision for the Drug Development. - | |||
| NCT02567578 Details | 2022-01-13 Interventional | 2 | 12 | YH12852 Dyspepsia Functional Dysp… | Technology transfer - | |||
| NCT04125745 Details | 2022-01-12 Interventional | 2 | 1 | CXA-10 Familial Primar… Hypertension Pulmonary Arter… | negative study outcome from Complexa's multicenter clinical trial; no safety concerns The clinical trial was terminated early due to lack of efficacy based on the negative study outcome from the drug company's multicenter clinical trial. Early termination leading to small numbers of subjects analyzed. | |||
| NCT01509339 Details | 2022-01-12 Interventional | 1 | 0 | Vancomycin Cystic Fibrosis Fibrosis Respiratory Asp… Methicillin-res… | Lab unable to measure vancomycin levels in Sputum - | |||
| NCT00321100 Details | 2022-01-12 Interventional | 2 | [1 Refs] | 23 | Bevacizumab Capecitabine Cetuximab Oxaliplatin Colorectal Neop… | Enrollment closed 10/15/2008 based on data about KRAS. - | ||
| NCT04653389 Details | 2022-01-11 Interventional | 2 | 10 | Immunomodulatin… Carcinoma Carcinoma, Hepa… Hepatocellular … | The treatment efficacy was not satisfactory. - | |||
| NCT04296942 Details | 2022-01-11 Interventional | 1 | 1 | Ado-Trastuzumab… Entinostat Maytansine Trastuzumab Breast Neoplasm… Triple Negative… Breast Cancer HER2+ Breast Ca… Hormone Recepto… Metastatic Brea… Triple Negative… | One participant was accrued, and the study was stopped due to new safety data from the company
for M7824 and slow accrual. - | |||
| NCT04278872 Details | 2022-01-11 Interventional | 2 | 13 | SJX-653 Hot Flashes | The study was terminated early as the goal of determining a safe and efficacious dose for
further development for the treatment of VMS was not met - | |||
| NCT03269409 Details | 2022-01-11 Interventional | 1 | 8 | Coal Tar Osteonecrosis | Logistical delays from device manufacturer due to COVID - | |||
| NCT03168438 Details | 2022-01-11 Interventional | 1 | 6 | Cyclophosphamid… Fludarabine Pembrolizumab Multiple Myelom… Neoplasms, Plas… Neoplasms | The study was terminated following an internal review of the company's research and development
portfolio - | |||
| NCT02901483 Details | 2022-01-11 Interventional | 1/2 | 12 | Cisplatin Head and Neck N… Squamous Cell C… Head and Neck S… | bussiness reason - | |||
| NCT02874651 Details | 2022-01-11 Interventional | 2 | 25 | Apatinib Carcinoma Epstein-Barr Vi… Nasopharyngeal … Nasopharyngeal … | Unacceptable toxicity (nasopharynx necrosis and massive hemorrhage) - | |||
| NCT02465593 Details | 2022-01-11 Interventional | 1/2 | [1 Refs] | 32 | Capecitabine Fluorouracil Rectal Neoplasm… Rectal Cancer | - - | ||
| NCT02079948 Details | 2022-01-11 Interventional | 2 | 0 | Folic Acid Methotrexate Vitamin B Compl… Inflammation Aging | Potential participants had concerns about taking the study drug (methotrexate). - | |||
| NCT04931667 Details | 2022-01-10 Interventional | 3 | 73 | Lorecivivint Osteoarthritis Osteoarthritis,… Osteoarthritis … | Study was terminated due to business reasons by Sponsor. - | |||
| NCT04044781 Details | 2022-01-10 Interventional | 1 | 0 | BPN14770 To Determine Br… | Change in Research Direction - | |||
| NCT03539601 2018-001043-31 Details | 2022-01-10 Interventional | 4 | 237 | Hydrocortisone Hydrocortisone-… Pimecrolimus Dermatitis Dermatitis, Ato… Eczema Atopic Dermatit… | This decision was made for business reasons only and is not related to any safety concerns
regarding crisaborole. Study was terminated early by sponsor. Decision was not due to safety/efficacy concerns, but was related to business, portfolio reprioritization. Sub-study planned as per Amendment 3 was not initiated, as sub study site setup didn't complete prior to study termination. |